Protein inhibitors of proteolytic enzymes regulate proteolysis and prevent the pathological effects of excess endogenous or exogenous proteases. Cysteine proteases are a large family of enzymes found throughout the plant and animal kingdoms. Disturbance of the equilibrium between cysteine proteases and natural inhibitors is a key event in the pathogenesis of cancer, rheumatoid arthritis, osteoporosis, and emphysema. A family (I42) of cysteine protease inhibitors (http://merops.sanger.ac.uk) was discovered in protozoan parasites and recently found widely distributed in prokaryotes and eukaryotes. We report the 2.2 Å crystal structure of the signature member of the I42 family, chagasin, in complex with a cysteine protease. Chagasin has a unique variant of the immunoglobulin fold with homology to human CD8a. Interactions of chagasin with a target protease are reminiscent of the cystatin family inhibitors. Protein inhibitors of cysteine proteases may have evolved more than once on nonhomologous scaffolds.
INTRODUCTION
Cysteine proteases are a large and diverse family of enzymes found throughout the plant and animal kingdoms, and represent the dominant protease family in invertebrates. Disturbance of the equilibrium between cysteine proteases and their natural inhibitors is a key event in the pathogenesis of cancer, rheumatoid arthritis, osteoporosis, and emphysema Riese and Chapman, 2000) . Chagasin is a protease inhibitor that was first identified in Trypanosoma cruzi as the physiological regulator of cruzain (also known as cruzipain), the major protease of this protozoan parasite Rigden et al., 2002; Sanderson et al., 2003) . Cruzain is a papain-like (Clan CA) cysteine protease that is expressed in all stages of the parasite life cycle. It is a key virulence factor of T. cruzi, the infectious agent responsible for the leading cause of heart disease in Latin America, Chagas disease (Scharfstein et al., 1986; Engel et al., 1998) . Chagasin is associated with cruzain during its trafficking to specific compartments of the parasite cell, and accumulated evidence suggests that the primary role of chagasin is in posttranslational regulation of protease activity . Following the discovery of chagasin, homologous proteins were identified in numerous other eukaryotic and prokaryotic organisms (Rigden et al., 2002; Sanderson et al., 2003) . In many cases, these related protease inhibitors likely regulate cysteine proteases produced by their cognate organism. However, in organisms such as the pathogenic bacterium Pseudomonas aeruginosa, a chagasin-like inhibitor is present but no gene encoding a cysteine protease target has been identified in the genome (Sanderson et al., 2003) . An alternative function for this family of protease inhibitors was therefore proposed: inhibiting the activity of host cysteine proteases elaborated as part of the host defense against pathogens (Sanderson et al., 2003) . The amino acid sequence of chagasin provides few clues to its function, as chagasin and other I42 family inhibitors share no sequence homology with any known protease inhibitors (Rigden et al., 2002) .
Recently, NMR solution structures were solved for chagasin (Salmon et al., 2006) and the homolog of chagasin in Leishmania mexicana (Smith et al., 2006) . Predictions were made about the possible mode of interaction between members of this new family of inhibitors and their protease targets. But without a protease-inhibitor complex, these remained speculative predictions. Solving of an X-ray structure of chagasin in complex with a target cysteine protease now allows clarification of the binding mode of this novel inhibitor.
RESULTS

Confirmation that Recombinant Chagasin Inhibits Target Proteases and Purification of the Chagasin-Falcipain 2 Complex
Before embarking on crystallization and structure analysis of the complex between chagasin and falcipain 2 (FP2), we confirmed that chagasin was indeed a tight-binding inhibitor of this parasite protease as well as homologous cathepsin L-like proteases (Table 1) . Chagasin was, in fact, a more potent inhibitor than the cystatins against five cathepsin L-like proteases. As was the case with cystatin, the K i versus cathepsin B was substantially higher due to the impediment of the occluding loop of cathepsin B to binding of protein inhibitors versus the small peptide inhibitor leupeptin. Having confirmed tight binding of chagasin to FP2, we then confirmed purification of that complex for crystallography and subsequent structural analysis ( Figure 1 ).
General Characteristics of the Chagasin-Falcipain 2 Structure: Chagasin Is a New Variant of the Immunoglobulin Fold The coordinates and structure of chagasin have been deposited in the Protein Data Bank (PDB) under ID code 2OUL. The X-ray structure of chagasin is found to differ from the structures of all known classes of protease inhibitors, including cystatin, staphostatin, and p41 (Bode et al., 1988; Dubin et al., 2003; Guncar et al., 1999) . Chagasin adopts an immunoglobulin (Ig)-like b sandwich structure ( Figure 2B ). Most Ig-like b sandwich domains are categorized into four subgroups: constant-type, variable-type, switched-type, and hybrid-type, as defined by the topological arrangement of the strands in the front and back b sheets (Bork et al., 1994) . The hypervariable loops connecting the b strands are the complementarity determining regions (CDRs) that contribute to the versatility of Ig-like folds in numerous protein-protein interactions (Garcia et al., 1998 (Garcia et al., , 1999 . In chagasin, the CDR equivalent loops 
Figure 1. Stoichiometry Analysis of Chagasin-FP2 by Size-Exclusion Chromatography
The standard curve based on molecular weight standards and the elution volume for the chagasin-FP2 complex and chagasin alone are highlighted. The peak fraction containing the putative complex was analyzed by SDS-PAGE followed by silver staining. The apparent molecular weights for the chagasin-FP2 complex and chagasin alone were calculated as 46 kDa and 14 kDa, respectively. The molecular weight for FP2 is 28 kDa.
Structure
Structure of Chagasin are the BC, DE, and FG loops (Figures 3B and 3C) . These loops approximately correspond to the three most conserved motifs defined in the I42 family of inhibitors (Rigden et al., 2002) , which indicates that the inhibition mechanism detailed in the current structure is likely to apply to the entire family of inhibitors. The immunoglobulin fold (i.e., the Ig-like fold) derives its name from the core structure of the immunoglobulins themselves, but it is also found in other immune system proteins including interleukin 1, CD4, CD1, and CD8. The elucidation of the structure of chagasin confirms that this backbone has utility for protein-protein interactions that is much broader. A query on DBAli (Marti-Renom et al., 2001) (http://salilab.org/DBAli/), with no restriction on sequence identity, shows that there are 284 chains in the PDB with more than 50% equivalent positions to the structure of chagasin. Among the proteins identified with high similarity to chagasin, 11 of the 31 are immune system proteins. A structural core of four conserved b strands, B, C, E, and F, constitute one of the signature features of an Ig-like fold. This conserved core is found in all subtypes of Ig domains, but on first analysis it appeared to be absent in chagasin because the N-terminal strand A in chagasin is positioned differently from known Ig-like domains. If strand A were switched from its traditional front-sheet position to the back sheet, the topology arrangement of chagasin would be identical to that of a typical c-type Ig domain ( Figure 3A ). We therefore classify the novel topology arrangement in chagasin as an Nsc-type Ig domain (amiNo-terminal switched constanttype).
Comparison of Chagasin X-Ray and Solution Structures
The Ig-like b sandwich structure of chagasin largely validates previous modeling predictions (Rigden et al., 2001) and two solution structures (Salmon et al., 2006; Smith et al., 2006) . However, differences exist at the N terminus and among the CDR-like loops. Sequence alignment suggests that other chagasin-like protease inhibitors also adopt similar Ig-like folds, and this is confirmed at least for the NMR solution structure for L. mexicana ICP (Salmon et al., 2006) . Structural variations are expected due to sequence inserts between strands D and E (Rigden , 2002) . For example, the chagasin ortholog from Plasmodium falciparum contains an insert of 50 amino acids between its motifs I and II that may introduce significant structural deviation, or even include an additional domain.
Homology of Chagasin and CD8a
The chagasin X-ray structure confirms homology to the X-ray structure of the T cell (thymus-derived lymphocyte) surface protein CD8a (Leahy et al., 1992) , a key element in antigen activation of T cells by antigen presenting cells.
The v-type Ig-like domain in CD8a has a topology arrangement very similar to that of chagasin ( Figures 3A and 3B ). Like CD8a, the b strands in chagasin are held together by strong hydrophobic interactions. Residues such as Val, Phe, Trp, Leu, and Ile constitute a solid hydrophobic core that likely ensures the stability of chagasin in the absence of any disulfide bond ( Figure 3C ). More importantly, the BC loop in chagasin (LPSNPTTGFAW) closely resembles the sequence of one of the CDR loops in human CD8a (LLSNPTSGCSW) ( Figure 2C ). What is most remarkable is that, to date, the sequence motif found in the binding loop of CD8a and chagasin has not been found in any of the other immunoglobulin superfamily members, including the 284 chains in the PDB with at least 50% of their residues structurally equivalent to those in chagasin.
An analysis of the binding of the chagasin BC loop to a target protease, compared to the binding of CD8a to a major histocompatibility complex (MHC), shows that four of the seven conserved residues play very similar roles (protein-protein interactions, flexibility or stabilization of the loop, and stabilization of the core). It is noteworthy that this short yet important sequence homology could not be detected using sensitive search engines such as PSI-BLAST but only became apparent after the structural homology was revealed. The BC loop is one of the three signature motifs of the I42 family of inhibitors, and it at least partially accounts for the activity of the inhibitor against target proteases ( Figure 3C) . A synthetic version of the BC loop peptide in the chagasin-like protein from Entamoeba histolytica specifically blocked the activity of cysteine proteases that prefer Phe at the P1 site (Riekenberg et al., 2005) . It is also noteworthy that Thr31 in the BC loop of chagasin binds to the catalytic Cys at the FP2 active site through water-mediated hydrogen bonds ( Figure 4A ). This highly conserved Thr likely serves as How Chagasin Binds to a Target Protease Models of the binding loops and predictions of interaction of these loops with target proteases were made based on two solution structures, one of chagasin itself (Salmon et al., 2006) and the other of the homolog from L. mexicana (Smith et al., 2006) . As expected from the observed flexibility of these loops in solution, the modeled structures differ from those determined here by X-ray analysis. Nevertheless, the BC loop, the highly mobile DE loop, and the RPW/F motif in the FG loop are all confirmed as key elements for binding. The previous report of the lack of inhibitor activity by a mutant form of the L. mexicana ICP highlights the importance of the GXG motif in the DE loop (Smith et al., 2006) . However, as shown in the X-ray analysis, a wedge-like interaction with the target by all three loops is key to binding and, by inference, full inhibition activity of chagasin.
Despite its clear homology to the LLSNPTSGCSW motif in human CD8a, the BC loop in chagasin appears to function via a different mechanism from what has been estab-lished for the CDR loops. Chagasin demonstrates a strict 1:1 binding to a target protease, FP2, in structure (Figure 4A) and in gel-filtration analysis (Figure 1 ). Both human and mouse CD8a form dimers that bind MHCs (Garcia et al., 1996; Gao et al., 1997; Liu et al., 2003) (Figure 4B ). In CD8a, these interactions rely upon the CDR loops and include the BC loop motif from each CD8a monomer (Gao et al., 1997; Liu et al., 2003) . By definition, the CDR loops adopt multiple conformations to complement antigen binding; thus, it is no surprise that the BC loop in chagasin and the equivalent loops in human and mouse CD8a have different structural features ( Figures 4A and 4B ). Mouse CD8a, at concentrations up to 1 mM, did not inhibit the proteases cruzain or FP2 (data not shown). Conversely, chagasin does not compete with binding of CD8a to an MHC by biacore analysis (H. Cheroutre, personal communication) or in a T cell activation assay.
DISCUSSION
The structure of chagasin was determined bound to the cathepsin L-like cysteine protease FP2 (Figure 2A) . The original FP2 structure was determined in a cystatin-FP2 (Wang et al., 2006) . Overall, the structural difference between chagasin-bound FP2 and cystatin-bound FP2 is minimal, with a root-mean-square deviation (rmsd) around 0.5 Å when compared by all 241 Ca atoms, suggesting that both inhibitors interact with a consistently folded protease.
The protease binding loops (BC, DE, and FG) in chagasin form a well-aligned wedge that fills the active site groove of target cysteine proteases to obstruct substrate binding. The tripartite binding in chagasin is reminiscent of that found in the cystatins (Bode et al., 1988; Wang et al., 2006) . Similar interactions are found between human cathepsin L and the MHC class II-associated p41 Ii fragment (Guncar et al., 1999) . Kinetic analysis confirms the advantage of tripartite binding. Chagasin inhibits both papain and cruzain with picomolar affinity . It also inhibits the malarial cysteine proteases FP2 and falcipain 3 (FP3), as well as the human cathepsins B, H, K, and L (Table 1) .
Chagasin, cystatins, and p41 inhibitory fragment come from protist, vertebrate, and human sources, respectively. They share no overall sequence homology and contain no conserved binding motifs. Nevertheless, they have evolved to bind to the same class of enzymes via remarkably similar binding interactions ( Figures 5A and 5B) . The tripartite mode of inhibition effectively blocks enzymatic activities in papain-like cysteine proteases and provides unique advantages that may have driven such evolutionary convergence. First, all tripartite binding results in very large protein-protease interaction surfaces that often correspond to strong binding energy. All known tripartite inhibitors bind to target cysteine proteases over buried surface areas larger than 2000 Å 2 ( Figure 5A) , whereas most other enzyme-inhibitor complexes only interact over surfaces averaging approximately 950 Å 2 in size (Jones and Thornton, 1996) . Second, the three protease contact sites are discontinuous in amino acid sequence and relatively independent from each other ( Figure 5B ). This organization, which is reminiscent of the versatility of antibodies in antigen binding, enables chagasin to adapt to the active sites of different cysteine proteases and likely accounts for its broad inhibitory activities. Third, it is intriguing that such multiloop binding interactions at the protease active site are only found between papain-like enzymes and their inhibitors (Stubbs et al., 1990; Jenko et al., 2003; Guncar et al., 1999; Wang et al., 2006) . By comparison to other protease classes, papainlike cysteine proteases harbor many characteristics that facilitate protein-protein interactions, including an accessible active site, a relatively flat substrate binding cleft, and the predominantly hydrophobic nature of the binding surface (Jones and Thornton, 1996; DeLano et al., 2000) .
The convergent evolution of chagasin, p41 inhibitory fragment, and cystatin reflects the importance of posttranslational regulation of cysteine proteases in organisms as ancient as protists and as complex as primates. In both T. cruzi and mammalian cells, these inhibitors have a commonality of function and location in that they interact with their target proteases in protein-trafficking pathways between the Golgi (chagasin) and the lysosome (cystatins). While the chagasin family proteins commonly function to inhibit endogenous papain-like cysteine proteases (Santos et al., 2005) , there are clearly examples of organisms without such enzymes in which a chagasin family inhibitor is produced (Pseudomonas aeruginosa and Thermobifida fusca, for example). In situations where a pathogen is involved, Sanderson et al. (2003) suggested that the chagasin homolog may function to protect the organism from host proteases elaborated as part of an innate immune response or other defense mechanism. Nevertheless, there are also examples of chagasin family inhibitors being expressed by nonpathogenic organisms such as the archae Methanosarcina acetivorans.
Functional convergence may account for the binding of an Ig-like inhibitor such as chagasin to its target proteases. It is more challenging to explain why distant proteins such as chagasin and CD8a share structural and sequence homology. It is possible that they share a common ancestor but have diverged in function. The highly homologous loops evolved to meet different functional requirements in protease binding and antigen presentation. An alternative hypothesis has also been proposed, invoking a horizontal gene transfer mechanism from human to the parasite, but it remains speculative without significant supporting nucleotide sequence data (Rigden et al., 2001 (Rigden et al., , 2002 . Alternatively, the discovery of homology between chagasin and CD8a suggests that a very effective and commonly used scaffold for protein binding, the Ig-like fold, arose in ancient eukaryotes. Because of the physical principles that hold b sheets within the Ig-like fold, the overall scaffold can remain stable yet diversify in the loop structures to provide novel biologic functions with specific binding partners. In the case of CD8a and chagasin, this led to a very similar motif presented by two different loops but interacting with the target ligand using four of seven similar amino acid side-chain modes. Protein-protein interactions using this scaffold likely diverged into distinct functional entities (enzyme inhibitors versus receptor binding cofactors) prior to or concurrent with the evolution of the adaptive immune system in vertebrates.
Conclusion
In conclusion, the specific mode of binding that confers inhibitory activity to chagasin and by analogy other members of this new inhibitor family is now clarified by X-ray structure. Predictions made from solution structures and mutagenesis studies are confirmed or corrected. Two important aspects of the molecular evolution of cysteine protease inhibitors are also mirrored in the structure. First, the homology between chagasin and CD8a suggests that a very effective and commonly used scaffold for protein binding arose in agent eukaryotes, but diverged into distinct entities (inhibitors versus binding cofactors) with the evolution of the adaptive immune system in vertebrates. Second, the tripartite loop interaction demonstrated between chagasin and a target protease appears to be a particularly effective and commonly used binding mode reflected in the convergent evolution of similar target binding by chagasin, p41 inhibitory fragment, and cystatin.
EXPERIMENTAL PROCEDURES
Cloning, Expression, Purification, Gel Filtration, and Kinetic Analysis of Chagasin Two primers (5 0 -CTTAAAATCGGATCCCACAAGGTGACGAAAGCCC ATAAC-3 0 and 5 0 -CCCAAGCTTGGGTCAGTTTGCCTTGAGATATACA GTGAA-3 0 ) were used to amplify the chagasin gene from T. cruzi chromosomal DNA. It was subsequently inserted between the BamHI and HindIII restriction sites in the pQE30 vector (QIAGEN). Upon transformation into m15 (pREP4) cells, the 12 kDa chagasin was expressed as an insoluble protein at 37 C, and was partially solubilized by slower cell growth in LB at 15 C. Soluble chagasin was then purified by an N-terminal His tag on an Ni-NTA column (QIAGEN) preequilibrated with 25 mM imidazole, 50 mM phosphate (pH 7.0), and 200 mM NaCl. Pure chagasin was eluted with a 100 mM-1 M imidazole gradient in the presence of equilibrium buffer.
The apparent K i of chagasin against FP2, FP3, and cathepsin B, H, K, and L was determined by standard protocols (Wang et al., 2006) .
Purification and Crystallization of the Chagasin-FP2 Complex
Purified and activated FP2 was incubated with recombinant chagasin at 4 C and further purified as previously described (Wang et al., 2006) . The purified chagasin-FP2 complex was dialyzed into 50 mM phosphate buffer (pH 7.0) and 200 mM NaCl and concentrated to 6 mg/ ml. The complex was subsequently crystallized by the sitting drop vapor diffusion method by mixing 0.8 ml of chagasin-FP2 with 0.8 ml of well solution at 4 C in the presence of 20% (v/v) PEG300, 0.1 M Tris (pH 8.5), 5% (w/v) PEG8000, and 10%-15% (v/v) glycerol. Molecular weight standards (Bio-Rad) and a preincubated mixture of chagasin-FP2 were analyzed by size-exclusion chromatography on a Superose 12 column (Pharmacia) in 50 mM Bis-Tris (pH 5.6) with 200 mM NaCl at a flow rate of 0.5 ml/min.
Data Collection and Structure Determination of the Chagasin-FP2 Complex
Crystals of chagasin-FP2 were directly flash-cooled in liquid N 2 for cryoprotection against synchrotron radiation. Complete data sets of chagasin-FP2 were collected at 100K on beamline 8.3.1 at the Advanced Light Source (ALS), using a CCD camera. The data sets were indexed and integrated using DENZO/SCALEPACK (Otwinowski and Minor, 1997) to yield a data set 96.7% complete at 2.2 Å (R merge = 10.8%). The chagasin-FP2 crystals belong to the space group P4 3 2 1 2, with cell dimensions a = b = 94.236 Å , c = 119.764 Å , and a = b = g = 90 . Each asymmetric unit contains only one chagasin-FP2 complex. Data up to 3.5 Å were included in the molecular replacement search with an FP2 model (PDB ID code 1YVB), using the rotational and translational functions from the Crystallography & NMR System software suites (CNS 1.1) (Brunger et al., 1998) . Following a rigid body refinement, the FP2 model gave an initial R working of 42.9%. Chagasin was built into the extra electron densities by de novo building using QUANTA 2000 (Molecular Simulations). The chagasin-FP2 structure was refined by alternate cycles of energy minimization, simulated annealing, and group B factor refinements in the CNS suites. Model building and fitting were done using QUANTA 2000. The final chagasin-FP2 structure has been refined to 2.2 Å . Complete data and refinement statistics are listed in Table 2 .
Sequence and Structure Homology Analyses
Various segments of the chagasin amino acid sequence were used to search against the general nonredundant database as well as the PDB database using the NCBI BLAST site for possible protein homologs. Results from the first search include similar protease inhibitors from other parasitic organisms, for example T. brucei and P. falciparum. Although a search against the PDB database identified scores of proteins from the immune system, regardless of which segment was used to search the PDB database, CD8a was always identified as one of the top hits. Alignment of the chagasin and CD8a sequences revealed that CD8a harbors a short sequence motif that is highly similar to motif I in chagasin.
The structure of chagasin was searched against the DABli database (http://www.salilab.org/DBAli/) to identify all known structures with significant structural similarity to chagasin (i.e., with p value > 8.0). DBAli contains 1,086,905,585 pairwise structural alignments and family-based multiple structure alignments for 26,950 nonredundant chains in the PDB. Three of the six matches are classified as immunoglobulins in SCOP (http://scop.mrc-lmb.cam.ac.uk/scop/; including the highest significance hit): one belongs to the PaPD superfamily of the Ig-like fold, and the remaining two are classified as non-Ig-like but b sheet-containing folds. Therefore, the available evidence suggests that chagasin belongs to the immunoglobulin superfamily with a very ancient divergence.
T Cell Cytotoxicity Assay
Cytotoxic activity was measured in a standard 51 Cr release assay. Activated CD8 + T cells from OT-I transgenic mice were used as effectors, generated as in Krummel et al. (1999) , and LB27.4 B cells were used as targets for cytotoxicity. Target B cells were labeled with 50 milliCi of 51 Cr per 1 3 10 6 cells for 1 hr. One milligram/milliliter of SIINFEKL cognate ovalbumin-derived peptide (pOVA) was added to the target cells during 51 Cr labeling followed by extensive washing. Different concentrations of chagasin protein were diluted in the wells for the cytotoxicity assay. In addition, one group of target cells was preincubated with 50 mg/ml of chagasin protein for 1 hr. Various dilutions of OT-I effector cells were incubated with 1 3 10 4 51 Cr-labeled target B cells in round-bottom 96-well plates for 4 hr at 37 C. Subsequently, 100 ml of supernatant was removed and counted on a scintillation counter to determine experimental 51 Cr release (ER). Spontaneous release (SR) was determined using the target cells alone, while maximum release (MR) was determined by lysing target cells with 1% SDS and measuring the amount of 51 Cr release. Specific lysis (in %) was calculated as follows: (ER À SR)/(MR À SR)*100. All samples were set up in triplicate. a Statistics for the highest-resolution shell. b R merge = P j(I -<I>)j/ P (I). c R = P h,k,l (jF obs (h,k,l)j -kjF calc (h,k,l)j)/ P h,k,l jF obs (h,k,l)j. d R free : crossvalidation R calculated by omitting 5% of the reflections (Kleywegt and Brunger, 1996) .
